Maria Zannes, Founder and CEO of bioAffinity Technologies, has developed a noninvasive diagnostic test to screen for early-stage lung cancer. The test uses porphyrin to label cells to find cell populations with cancer cells. Using mucus from the lungs, this is a second test for people who are at high risk, giving them a chance to avoid more invasive procedures to determine their risk level and if they have lung cancer.

Maria explains, "The combination of being able to determine that cancer is present in the lungs with our test, coupled with the noninvasive nature of the test itself really spoke to me. Having a test for early detection of lung cancer where the treatment can be so much more effective and people can live so much longer and healthier lives is compelling."

"It's very simple for the patient and the doctor. The patient would go in, let's say they had a positive low-dose CT, they weren't sure, and the physician would then give the patient a small box. It's a 5x5 box with a little collection cup inside. We have a patient coach, an individual who calls the patient, and helps them to provide a sample, often early in the morning. People out of a shower start to cough up a little bit of mucus."

"The results tell the physician whether the patient is at high risk or has lung cancer or does not, but also gives them a numerical score, so the physician himself or herself has a little bit more to go on than just a yes or no answer."

@bioAffinity #LungCancer #CancerDiagnostic #Medtech #Biotech #CancerTreatment #CancerDiagnosis 

bioaffinitytech.com

Listen to the podcast here